#USA #New York #Pomerantz LLP #SEC Investigation #PepGen Inc

Pomerantz Law Firm Investigates PepGen Inc. for Investor Claims

The Pomerantz Law Firm is currently conducting an investigation into possible securities fraud concerning PepGen Inc. (NASDAQ: PEPG). This probe is particularly aimed at determining whether the company’s executives have engaged in any unlawful business practices that may have affected investor interests.

Background of the Investigation

On March 4, 2025, PepGen made a noteworthy announcement regarding its decision to temporarily pause the Phase 2 CONNECT2-EDO51 study. This trial focuses on PGN-EDO51, a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD). The announcement prompted a notable decline in the company's stock price, which fell by $0.53, approximately 18.86%, closing at $2.28 per share on the same day. Such a drastic drop raises questions about the company's transparency and communication practices, particularly in how clinical trial updates impact stock performance.

Legal Implications

Pomerantz LLP is urging investors who feel they may have been impacted by PepGen's actions to reach out. They can turn to Danielle Peyton, who is directing the investigation, for assistance. The investigation seeks to ascertain whether PepGen or any of its officers misled investors or mismanaged the situation, which would constitute grounds for a securities fraud claim. The firm specializes in corporate, securities, and antitrust class actions, positioning it well to tackle such cases.

About Pomerantz LLP

Pomerantz, with offices spanning major financial cities such as New York, Chicago, Los Angeles, London, and Tel Aviv, has a significant history in advocating for victims of securities fraud. Since its founding by Abraham L. Pomerantz, the firm has honed its expertise in guiding investors through complex legal landscapes and recovering substantial damages for class members. The firm boasts more than 85 years of experience in handling complex securities class actions, making it a reputable choice for investors seeking to reclaim their losses.

What Investors Should Do

Investors who have stakes in PepGen Inc. should assess their positions, especially in light of the recent findings and stock fluctuations. If you or someone you know has been affected, participating in this investigation may not only provide clarity but also the opportunity for restitution. Those interested in joining the class action or seeking more information are encouraged to contact Danielle Peyton via email or phone as provided by the Pomerantz firm.

This investigation serves as a vital reminder for investors to remain vigilant regarding the corporate behaviors that could negatively affect their investments. Transparency and ethical communication should be the cornerstone of public companies, and investors have a right to advocate for their interests in this environment.

For future developments, it is advisable for affected parties to monitor updates from Pomerantz LLP as they may formally announce the next steps in the investigation and potential legal actions against PepGen. Investors should act promptly to ensure that their claims are duly filed and given attention in these concerning times.

Stay informed, as the unfolding of this situation could dictate future dealings with PepGen and similarly structured companies within the biotech space.